What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His primary scientific interests are in Internal medicine, Cancer research, Gastroenterology, PI3K/AKT/mTOR pathway and PTEN.
His Internal medicine study incorporates themes from Endocrinology and Surgery.
His Cancer research study combines topics in areas such as Cell growth, GSK-3, Immunology, Targeted therapy and Metastasis.
The study incorporates disciplines such as Hepatitis C, Complication, Immunopathology, Allergy and Pancreatic disease in addition to Gastroenterology.
His studies in PI3K/AKT/mTOR pathway integrate themes in fields like Protein kinase B and MAPK/ERK pathway.
His research investigates the connection between PTEN and topics such as Cancer stem cell that intersect with problems in Curcuma, Berberine, Curcumin and Resveratrol.
His most cited work include:
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health (423 citations)
- Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging (416 citations)
- GSK-3 as potential target for therapeutic intervention in cancer. (293 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Gastroenterology, Endocrinology, Cancer research and Hepatocellular carcinoma are his primary areas of study.
The Internal medicine study combines topics in areas such as Diabetes mellitus and Hepatitis C virus.
His research investigates the link between Gastroenterology and topics such as Coeliac disease that cross with problems in Intestinal mucosa.
In his work, Steatosis is strongly intertwined with Fatty liver, which is a subfield of Endocrinology.
He has included themes like Apoptosis, Protein kinase B, PI3K/AKT/mTOR pathway, Cell growth and MAPK/ERK pathway in his Cancer research study.
His Hepatocellular carcinoma research includes elements of Cancer, Carcinoma and Oncology.
He most often published in these fields:
- Internal medicine (56.30%)
- Gastroenterology (28.66%)
- Endocrinology (20.93%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (56.30%)
- Cancer research (20.73%)
- Hepatocellular carcinoma (16.67%)
In recent papers he was focusing on the following fields of study:
Giuseppe Montalto spends much of his time researching Internal medicine, Cancer research, Hepatocellular carcinoma, Cancer and Gastroenterology.
His research in Internal medicine intersects with topics in Diabetes mellitus, Endocrinology and Oncology.
His Cancer research research is multidisciplinary, incorporating elements of Protein kinase B, Pancreatic cancer, Targeted therapy, PI3K/AKT/mTOR pathway and MAPK/ERK pathway.
He combines subjects such as Interleukin 6 and Drug resistance with his study of Hepatocellular carcinoma.
His study in the field of Immunotherapy also crosses realms of Aglycone.
His work in the fields of Gastroenterology, such as Ascites, Portal vein thrombosis and Esophageal varices, intersects with other areas such as Univariate analysis.
Between 2017 and 2021, his most popular works were:
- Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. (135 citations)
- GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. (37 citations)
- Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. (29 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His scientific interests lie mostly in Cancer research, Cancer, Internal medicine, Immunotherapy and Hepatocellular carcinoma.
He combines subjects such as Cell, Cell culture, Pancreatic cancer, Apoptosis and Metastasis with his study of Cancer research.
His research in Internal medicine intersects with topics in Gastroenterology and Diabetes mellitus.
In general Gastroenterology study, his work on Steatosis often relates to the realm of Placebo-controlled study, thereby connecting several areas of interest.
The Immunotherapy study which covers Oncology that intersects with Omics and Immune checkpoint.
Giuseppe Montalto works on Hepatocellular carcinoma which deals in particular with Sorafenib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
